At the Icahn School of Medicine at Mount Sinai, the Human Immune Monitoring Center (HIMC) will use state-of - the-art high-throughput technology to test the therapeutic effects of Libtayo ® (cemiplimab-rwlc), a PD-1 antibody blockade developed by Regeneron Pharmaceuticals, Inc. and Sanofi.
While immunotherapy has revolutionized the field of oncology, key issues remain — such as learning more about how these drugs work in human cancer— and many patients are still failing to respond to these therapies, leaving a need for a better understanding of how FDA-approved immunotherapies work and how we can use emerging therapies to further improve treatment response rates. The HIMC will evaluate the clinical efficacy and response of patients to cemiplimab therapy in early-stage non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), and head and neck squamous cell carcinoma (HNSCC) in a Phase I clinical trial led by Thomas Marron, MD, PhD, Assistant Director of Early Phase and Immunotherapy Trials at the Tisch Cancer Institute at Mount Sinai. The HIMC will use tailored methods to extensively challenge the changes caused within the tumor by these novel therapies. Other methods include single-cell visualization of cancer lesions and circulating immune cells, tumor tissue spatial analysis, and pre-and post-treatment microbiome sequencing of the patient.
Led by Miriam Merad, MD, PhD, Director of Precision Immunology Institute and Co-Director of Cancer Immunology Program, Icahn School of Medicine's Tisch Cancer Institute in Mount Sinai, HIMC is using new proprietary technologies and tools to identify immune profiles and responses across a range of disease settings.
“We are a team of highly integrated scientists with distinct expertise in medicine, immunology, technology, mathematics and physics, whose goals are to dissect the contribution of the immune system to human diseases and use this knowledge to design novel immune-based therapies,” said Merad.
The HIMC currently supports over 45 federal and foundation-funded research programs across a diverse range of diseases including cancer, autoimmune disease, inflammatory bowel disease, allergy and neurodegenerative disease. It also serves as a central resource for several multi-institutional consortia including the NIH Human Immunology Project Consortium (HIPC), the Children’s Health Exposure Analysis Resource (CHEAR) and the Consortium of Food Allergy Research (CoFAR). The HIMC is also one of four NCI-designated Cancer Immune Monitoring and Analysis Center and is actively supporting 13 industry-sponsored research programs.
“The large body of expertise in immuno-oncology, as well as the foundational and innovative approach found within the HIMC and Dr. Merad’s team, strongly influenced our decision to work with Mount Sinai on this study,” said Gavin Thurston, Vice President of Oncology and Angiogenesis at Regeneron.
“The breadth and number of partnerships between the HIMC and leading academic and industry partners reflects the quality of cutting-edge, proprietary techniques and technologies developed by Dr. Merad and her team,” said Erik Lium, PhD, Executive Vice President of Mount Sinai Innovation Partners, the commercialization engine of the Mount Sinai Health System. “We look forward to expanding the HIMC and to broadly engaging with additional academic life science, biotech and pharma partners on transformative, groundbreaking research.”
About Mount Sinai Innovation Partners (MSIP)
Mount Sinai Innovation Partners (MSIP) is responsible for driving the real-world application and commercialization of Mount Sinai discoveries and inventions, and the development of research partnerships with industry. Our aim is to translate discoveries and inventions into health care products and services that benefit patients and society. MSIP is accountable for the full spectrum of commercialization activities required to bring Mount Sinai inventions to life. These activities include evaluating, patenting, marketing and licensing new technologies building research, collaborations and partnerships with commercial and nonprofit entities, material transfer and confidentiality, coaching innovators to advance commercially-relevant translational discoveries, and actively fostering an ecosystem of entrepreneurship within the Mount Sinai research and health system communities. For more information, please visit www.ip.mountsinai.org.
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest integrated delivery system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai's vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The Health System includes approximately 7,480 primary and specialty care physicians; 11 joint-venture ambulatory surgery centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools", aligned with a U.S. News & World Report's "Honor Roll" Hospital, No. 12 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of top U.S. hospitals; it is one of the nation's top 20 hospitals in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Geriatrics, Gynecology, Nephrology, Neurology/Neurosurgery, and Orthopedics in the 2019-2020 "Best Hospitals" issue. Mount Sinai's Kravis Children's Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 12th nationally for Ophthalmology and the South Nassau Communities Hospital is ranked 35th nationally for Urology. Mount Sinai Beth Israel, Mount Sinai St. Luke's, Mount Sinai West, and South Nassau Communities Hospital are ranked regionally.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.